Hello Regulatory Scientists,
Today, let’s explore the journey of Opdivo (nivolumab) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today.
Regulatory History and Initial Submission
Drug: Opdivo (nivolumab) Mechanism of Action: PD-1 inhibitor, which helps the immune system recognize and attack cancer cells Indication: Treatment of unresectable or metastatic melanoma Initial Submission Date: July 2014
The Complete Response Letter (CRL)
CRL Date: October 2014 CRL Concerns:
1. Data Maturity: The FDA requested more mature overall survival data from the pivotal clinical trial.
2. Long-term Safety: Concerns about the long-term safety profile and potential immune-related adverse events.
3. Manufacturing Process: Issues related to the consistency and quality of the drug’s manufacturing process.
Resubmission Strategy
Bristol-Myers Squibb, the company behind Opdivo, implemented a comprehensive strategy to address the FDA’s concerns:
1. Extended Data Collection: Collected and submitted more mature overall survival data from the pivotal clinical trial.
2. Enhanced Safety Monitoring: Provided additional long-term safety data and analyses, focusing on immune-related adverse events.
3. Improved Manufacturing Processes: Implemented improvements in the manufacturing process to ensure consistency and quality.
4. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions.
Resubmission Date: December 2014
Outcome
Approval Date: March 2015 Opdivo was approved for the treatment of unresectable or metastatic melanoma, marking a significant milestone in immuno-oncology.
Lessons Learned
The journey of Opdivo from CRL to approval highlights several key lessons for drug developers:
1. Mature Data Submission: Providing mature overall survival data is crucial for demonstrating the efficacy of oncology drugs.
2. Robust Safety Data: Ensuring comprehensive long-term safety data, particularly for immune-related adverse events, is essential to address FDA concerns.
3. Improved Manufacturing Standards: Ensuring the quality and consistency of the manufacturing process can prevent regulatory setbacks.
4. Effective Use of Advisory Committees: Leveraging advisory committees can provide valuable feedback and support the resubmission process.
5. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations.
Relevance for Current Drug Developers
For companies developing drugs today, the Opdivo case underscores the importance of strategic planning and meticulous data collection in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval:
1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including data maturity and manufacturing processes, meet FDA standards.
2. Proactive Data Collection: Identify and address potential gaps in clinical data early in the development process to prevent issues from arising during FDA review.
3. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process.
4. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns.
5. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission.
By learning from the Opdivo resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval.
Stay diligent and strategic,
CERES Regulatory Services
—
